AR025459A1 - Antagonistas muscarinicos - Google Patents

Antagonistas muscarinicos

Info

Publication number
AR025459A1
AR025459A1 ARP000104540A ARP000104540A AR025459A1 AR 025459 A1 AR025459 A1 AR 025459A1 AR P000104540 A ARP000104540 A AR P000104540A AR P000104540 A ARP000104540 A AR P000104540A AR 025459 A1 AR025459 A1 AR 025459A1
Authority
AR
Argentina
Prior art keywords
muscarinic antagonists
alkoxy
halogen
alkyl
substituents selected
Prior art date
Application number
ARP000104540A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR025459A1 publication Critical patent/AR025459A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP000104540A 1999-09-22 2000-08-31 Antagonistas muscarinicos AR025459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40139199A 1999-09-22 1999-09-22

Publications (1)

Publication Number Publication Date
AR025459A1 true AR025459A1 (es) 2002-11-27

Family

ID=23587566

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104540A AR025459A1 (es) 1999-09-22 2000-08-31 Antagonistas muscarinicos

Country Status (14)

Country Link
EP (1) EP1214299B1 (https=)
JP (1) JP2003509494A (https=)
CN (1) CN1167682C (https=)
AR (1) AR025459A1 (https=)
AT (1) ATE264301T1 (https=)
AU (1) AU5786300A (https=)
CA (1) CA2384018C (https=)
CO (1) CO5180624A1 (https=)
DE (1) DE60009931T2 (https=)
ES (1) ES2215055T3 (https=)
HK (1) HK1043590A1 (https=)
MX (1) MXPA02003136A (https=)
PE (1) PE20010649A1 (https=)
WO (1) WO2001021590A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
DE60213629T2 (de) * 2001-10-10 2007-10-18 Schering Corp. Piperidinverbindungen als muscarinantagonisten
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3371164B1 (en) 2015-11-06 2022-03-16 Neurocrine Biosciences, Inc. N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
AU756484B2 (en) * 1998-06-30 2003-01-16 Schering Corporation Muscarinic antagonists

Also Published As

Publication number Publication date
ES2215055T3 (es) 2004-10-01
CN1374949A (zh) 2002-10-16
AU5786300A (en) 2001-04-24
WO2001021590A1 (en) 2001-03-29
EP1214299B1 (en) 2004-04-14
DE60009931D1 (de) 2004-05-19
CA2384018C (en) 2010-01-12
CN1167682C (zh) 2004-09-22
CO5180624A1 (es) 2002-07-30
HK1043590A1 (zh) 2002-09-20
CA2384018A1 (en) 2001-03-29
EP1214299A1 (en) 2002-06-19
MXPA02003136A (es) 2002-09-30
ATE264301T1 (de) 2004-04-15
PE20010649A1 (es) 2001-06-19
JP2003509494A (ja) 2003-03-11
DE60009931T2 (de) 2005-04-07

Similar Documents

Publication Publication Date Title
MY133992A (en) Muscarinic antagonists
CN100415716C (zh) 1－(1，2－双取代哌啶基)－4－取代哌嗪衍生物
AU597188B2 (en) 2-{(4-piperidyl)methyl}-1,2,3,4-tetrahydro-9h-pyrido{3,4-b }indole derivatives, their preparation and their application in therapy
JP2024020453A (ja) Ｒｏｃｋ阻害剤としての重水素化合物
NO20061419L (no) Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser
NO990671D0 (no) Muskarinantagonistiske etere
AR025459A1 (es) Antagonistas muscarinicos
NO20005166D0 (no) Nye benzotiofen-, benzofuran- og indolforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem
PE20040687A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
CO5700720A2 (es) Derivados de n-(quinolin-5l) alquilamida-sustituida; n-alquilquinolin-5-carboxamida-sustituida; n-alquilisoquinolin-5-carboxamida-sustituida; n-(isoquinolin-5-yl) alquilamida-sustituida y procesos para su preparacion
AR035892A1 (es) Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos
RU2005114489A (ru) N-акрил-4-метиленамино-3-гидрокси-2-пиридоны в качестве противомикробных препаратов
RU2004130426A (ru) Циклические амиды
AR043501A1 (es) Derivados de imidazol-4-il-etinil-piridina
AR019167A1 (es) Derivados heteroaromaticos de piperazinas di-n-sustituidas y piperidinas 1,4-disustituidas, composiciones farmaceuticas y el uso de los mismos para lapreparacion de medicamentos
YU40998A (sh) Derivati supstituisanog 1,2,3,4-tetrahidronaftalina
US2846437A (en) Lower alkyl 4-phenyl-1-(substituted-alkyl) piperidine-4-carboxylates and preparationthereof
SE9703377D0 (sv) New compounds
DE3875866T2 (de) Sulfonamidolphenyl-derivate und diese enthaltende therapeutische und vorbeugend wirkende mittel gegen arrhythmie.
DE3878371T2 (de) Psychotropische bizyklische imide.
KR960022486A (ko) 신규 티아졸리딘-4-온 유도체
DE60105610D1 (en) Pyrazinonderivate
FI942976A0 (fi) 5-amino-8-metyyli-7-pyrrolidinyylikinoliini-3-karboksyylihappojohdannaiset
NZ543068A (en) Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them
ECSP003642A (es) Antagonistas muscarinicos